Clinical trials: Immune Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00706342
- Testing
- Fostamatinib Disodium / R935788
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Childhood Chronic Immune Thrombocytopenia
The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is an autoimmune disorder manifested as isolated low platelet count which results in a tendency for bleeding.
- Trial name
- NCT01226524
- Testing
- Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Hadassah Medical Organization
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Immune Thrombocytopenia
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
The investigators will attempt to further increase the cure rate of ITP with medical therapy by providing maintenance therapy with Mycophenolate mofetil (MMF) to persistent/chronic ITP patients after treating them with induction…
- Trial name
- NCT02649504
- Testing
- Rituximab, Dexamethasone, Mycophenolate mofetil
- Sponsor
- Weill Medical College of Cornell University
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx
Immune Thrombocytopenia, Treatment
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not…
- Trial name
- NCT07362238
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenic Purpura, Amegakaryocytic Aplasia
Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia
Investigate prevalence of splenomegally in patients with isolated thrombocytopenia. Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome To explain possible causes of…
- Conditions
- Primary Immune Thrombocytopenic Purpura, Amegakaryocytic Aplasia, Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia), Lymphoproliferative Disorder With Secondary ITP
- Trial name
- NCT07182760
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Primary Immune Thrombocytopenia, Sjögren's Syndrome
Managed Access Programs for VAY736, Ianalumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
- Trial name
- NCT07244289
- Testing
- ianalumab
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus eltrombopag compared to eltrombopag monotherapy for the first-line treatment of adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT05369377
- Testing
- Zanubrutinib, Eltrombopag
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University People's Hospital
Primacy Immune Thrombocytopenia
Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients affected of primary immune thrombocytopenia as first treatment to address the disease.
- Trial name
- NCT02402998
- Testing
- Eltrombopag
- Where
- 14 sites in Italy
- Volunteers
- 55 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Immune Thrombocytopenia
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Background: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder. Corticosteroids are first-line therapy, but about one-third of patients relapse or are refractory.
- Trial name
- NCT07687134
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results.
- Conditions
- Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
- Trial name
- NCT06665308
- Testing
- No intervention
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 97 people
- Sponsor
- Sanofi
Thrombocytopenia
Daclizumab to Treat Chronic Immune Thrombocytopenia
This study will evaluate the effectiveness of the drug daclizumab for treating patients with chronic immune thrombocytopenia (ITP), a disease in which the immune system destroys platelets (blood cells involved in the clotting…
- Trial name
- NCT00049725
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Immune Thrombocytopenia
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of age. This is a 2 part study.
- Trial name
- NCT04737850
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anti-CD20 Monoclonal Antibody, BTK Inhibitors
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
This study aims to utilize anti-CD20 monoclonal antibodies to eliminate peripheral B cells and reduce the mechanism of autoantibody production, as well as combine the mechanism of BTK inhibitors (BTKi) blocking the B cell…
- Conditions
- Anti-CD20 Monoclonal Antibody, BTK Inhibitors, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07574073
- Testing
- Anti-CD20 monoclonal antibody and the BTK inhibitor
- Volunteers
- 30 people
- Sponsor
- Qi deng
Autoimmune Disease, Autoimmune Hemolytic Anemia
Treatment of Autoimmune Thrombocytopenia (AITP)
Platelets are particles found along with red and white blood cells in the blood that play a role in the process of blood clotting.
- Conditions
- Autoimmune Disease, Autoimmune Hemolytic Anemia, Thrombocytopenia
- Trial name
- NCT00001630
- Testing
- Isolex 300i
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immune Thrombocytopenia
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
- Trial name
- NCT07104565
- Testing
- INCA000585
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 56 people
- Sponsor
- Incyte Corporation